Medicare Rx Final Regs Retain CMS Right To Plans’ Drug Price Information
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency releases final rules implementing Title I and II of the Medicare Modernization Act. CMS’ authority to evaluate data on drug prices negotiated by Medicare prescription drug plans does not violate the “non-interference” provision of MMA, reg states. Drug price reviews will be “rare,” CMS says.
You may also be interested in...
CMS’ McClellan To Discuss Medicare Rx With AARP Board Feb. 1
Agency chief will address the organization’s annual policy meeting less than two weeks after release of the final rules implementing Part D drug benefit. HHS Information Technology Coordinator Brailer is expected to discuss the e-prescribing draft rule.
CMS’ McClellan To Discuss Medicare Rx With AARP Board Feb. 1
Agency chief will address the organization’s annual policy meeting less than two weeks after release of the final rules implementing Part D drug benefit. HHS Information Technology Coordinator Brailer is expected to discuss the e-prescribing draft rule.
CMS Claims Too Much Authority Over Medicare Rx Prices – PhRMA
The Centers for Medicare & Medicaid Services incorrectly interprets the Medicare Modernization Act to allow "justification of aggregate price levels for groups of drugs," PhRMA asserts in comments on CMS' proposed Part D regs.